SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure 1. Demographics are not differentially associated with patient clusters.
AB) At DSO11, plasma concentration across four patient clusters of RBD-specific A) IgM or B) IgA. CD)
MELD representations of local enrichment across PHATE embedding, of C) critical severity or D) fatal outcome. E) Days in hospital among survivors of patient clusters. F) Age of patients per patient cluster.
G) Percentage of the whole cohort or per patient cluster which are female (hashed). H) Fraction of dominant ancestry per patient cluster, calculated from genotyping. N discovery cohort: 1 = 38; 2 = 49; 3 = 73; 4 = 82 (242 in total). ABEF) Kruskal-Wallis with Dunn's multiple comparison tests. GH) Chi2 tests.

Supplementary Figure 2. Kinetics of RBD-specific antibody responses per patient clusters. A) RBD-specific IgG levels at DSO20 (+/- 4 days) per patient cluster. **B)** Sigmoidal curve fitted to the average per day per patient cluster of RBD-specific IgG responses, along day since symptom onset, within the validation cohort. **C)** RBD-specific IgG levels at DSO20 (+/- 4 days) per patient cluster of the validation cohort. **DE)** Model and statistical comparisons of RBD-specific D) IgM and E) IgA of the discovery cohort. **F)** Fraction of patients per cluster with at least one sample with detectable plasma vRNA (>13 copies/mL, saturated pie slices) throughout hospital stay. N discovery cohort: 1 = 38; 2 = 49; 3 = 73; 4 = 82 (242 in total). N validation cohort: V1 = 37; V2 = 39 (76 in total). A) Kruskal-Wallis with Dunn's multiple comparison tests. B) Mann-Whitney test. DE) Two-stage bootstrap, with 1000 simulations. Pairwise comparisons between all four clusters.

Supplementary Figure 3. Similar plasma profiles at DSO11 between different outcomes of cluster 1 patients. A) Patients from PHATE embedding color-coded by outcome at DSO60, where mauve dots are fatal outcome, and pink dots are survivors. B-F) DSO11 levels, between survivors and non-survivors, of B) plasma vRNA; C) Cytokine score ; D) Tissue damage score and E) RBD-specific IgG ; F) ssGSEA COVID severity score. G) GSEA on Hallmark gene sets for the contrast survivor vs deceased within cluster 1 only. **H-I)** Gene ontology (GO) enrichments for the Biological Processes (BP) database for significantly upregulated (FDR < 0.01, logFC > 0) genes for contrasts H) 1 vs 2 or I) 3 vs 4. Only significant enrichments (FDR < 0.05) are shown. **J-L**) At DSO11, correlation between IFN score and contemporaneous **J**) vRNA; **K**) Cytokine Score or **L**) Tissue damage score. BCDEFJKL) N: 1 = 38; 2 = 49 ; 3 = 73, 4 = 82 (242 in total). GHI). N: 1 = 37 ; 2 = 35 ; 3 = 41, 4 = 61 (174 in total).BCDEF) Mann-Whitney test. JKL) Spearman correlation.

Supplementary Figure 4. Distribution of isotypes among RBD-specific antibody secreting cells. A) Representative gating strategy to identify B cells (CD19+ CD20+) or plasmablasts (CD19+/- CD20-CD11c- CD38+ CD27+). **B)** Representative gating strategy of RBD-specific PB per cluster. **C)** RBD gate on B cells from a convalescent subject. **D)** Frequency of B cells which are RBD-specific in all four acute COVID-19 clusters, uninfected donors (UC) or convalescent subjects (Conv). **E)** RBD gate on plasma cells from a convalescent subject. **F)** Frequency of PB cells which are RBD-specific in all four acute COVID-19 clusters, uninfected donors (UC), or convalescent subjects (Conv). **n** for cluster 1 = 14; 2 = 16; 3 = 12; 4 = 13; Conv = 3; UC = 5. **GH)** Correlation between ssGSEA COVID-19 severity score and absolute counts of RBD-specific G) B cells or H) PB. **IJ)** Pie chart of isotype expression among I) RBD-specific B cells or J) RBD-specific PB per patient clusters. **n** for cluster 1 = 14; 2 = 16; 3 = 12; 4 = 13; Conv = 3; UC = 5. **GH)** prepare clusters. **n** for cluster 1 = 14; 2 = 16; 3 = 12; 4 = 13; Conv = 3; UC = 5. **GH)** PB. **IJ)** Pie chart of isotype expression among I) RBD-specific B cells or J) RBD-specific PB per patient clusters. **n** for cluster 1 = 14; 2 = 16; 3 = 12; 4 = 13. DF) Kruskal-Wallis with Dunn's multiple comparison tests. GH) Spearman correlations. IJ) Permutation test (1000 iterations).

Supplementary Figure 5. Spike-specific T cell responses in acute and resolved COVID-19. A) PBMCs from acutely-SARS-CoV-2-infected individuals were stimulated with peptide pools of viral antigens (Spike – S , M or N) for 6hrs (addition of BFA 1 hour after stimulation). Representative gates on cytokine+ CD4⁺ or CD8⁺ T cells. **B)** Net frequency of SARS-CoV-2-specific CD4⁺ T cells, as calculated using a Boolean OR gate on CD69 vs CD40L, IFNγ, IL-2, IL-10, IL-17, or TNFα. **C)** Net frequency of SARS-CoV-2-specific CD8⁺ T cells, as calculated using a Boolean OR gate on CD69 vs CD107a, IFN γ or TNF α . **D**) Following 9hrs stimulation of PBMCs with Spike peptide pool, representative gating strategy for identify CD4⁺ or CD8⁺ T cells using AIM panel. **EF**) Frequency of **E**) CD4⁺ T or **F**) CD8⁺ T cells which are Spike-specific in all four acute COVID-19 clusters, uninfected donors (UC), or convalescent subjects (Conv). C) n = 26 COVID-19+ acute samples (3 were excluded due to incomplete sampling). EF) n for cluster 1 = 11; 2 = 13; 3 = 9; 4 = 11; Conv = 5; UC = 5. C) Friedman test, with Dunn's multiple comparison test. EF) Kruskal-Wallis with Dunn's multiple comparison tests.









